Skip to main content

Xospata FDA Approval History

Last updated by Judith Stewart, BPharm on Nov 28, 2018.

FDA Approved: Yes (First approved November 28, 2018)
Brand name: Xospata
Generic name: gilteritinib
Dosage form: Tablets
Company: Astellas Pharma US, Inc.
Treatment for: Acute Myeloid Leukemia

Xospata (gilteritinib) is a FLT3/AXL kinase inhibitor indicated for the treatment of patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.